Dofetilide: A new pure class III antiarrhythmic agent
Authors:
- Rodney H. FalkRFRodney H. Falk
- Jeanne M. DeCaraJDJeanne M. DeCara
- 1 November 2000
- journal article
- review article
- Published by Elsevier in American Heart Journal
- Vol. 140 (5) , 697-706
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Effects of Dofetilide, a Class III Antiarrhythmic Drug, on Various Ventricular Arrhythmias in DogsJournal of Cardiovascular Pharmacology, 1996
- Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization*Clinical Pharmacology & Therapeutics, 1995
- Dofetilide reduces the incidence of ventricular fibrillation during acute myocardial ischaemia. A randomised study in pigsCardiovascular Research, 1994
- Differential Effects of the New Class III Agent Dofetilide on Potassium Currents in Guinea Pig CardiomyocytesJournal of Cardiovascular Pharmacology, 1994
- Pharmacodynamics and Pharmacokinetics of the Class III Antiarrhythmic Agent Dofetilide (UK-68,798) in HumansJournal of Cardiovascular Pharmacology, 1993
- Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectorisThe American Journal of Cardiology, 1992
- Electropharmacology of dofetilide, a new class III agent, in anaesthetised dogsEuropean Journal of Pharmacology, 1992
- Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and manXenobiotica, 1992
- Rate and concentration‐dependent effects of UK‐68,798, a potent new class III antiarrhythmic, on canine Purkinje fibre action potential duration and VmaxBritish Journal of Pharmacology, 1991
- Pharmacokinetic and pharmacodynamic effects of UK‐68,798, a new potential class III antiarrhythmic drug.British Journal of Clinical Pharmacology, 1991